
Browsing restrictions can be lifted for a fee.
-3.12%
Invo fertility, inc.
3.59%
Avg of Sector
-1.22%
S&P500

Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2026Q1 | ||||
| 2026Q2 | ||||
| 2026Q3 | ||||
| 2026Q4 | ||||
| 2027Q1 |
INVO Fertility, Inc., formerly known as NAYA Biosciences, Inc., is a healthcare services fertility company dedicated to expanding assisted reproductive technology (ART) care. The company focuses on building, acquiring, and operating fertility clinics, including “INVO Centers” offering the intravaginal culture (IVC) procedure enabled by its proprietary INVOcell® medical device. This device allows fertilization and early embryo development to occur in vivo within the woman’s body, providing a more natural, intimate, and affordable alternative to traditional IVF. INVO Fertility operates multiple centers in the U.S. and distributes the INVOcell technology to third-party clinics. The company separated its fertility and oncology businesses in April 2025 to focus exclusively on fertility care.
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2025Q4 | |||||||
| 2025Q3 | |||||||
| 2025Q2 | |||||||
| 2025Q1 |
The most recent financial report for Invo fertility, inc. (IVF) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IVF's short-term business performance and financial health. For the latest updates on IVF's earnings releases, visit this page regularly.
According to the latest financial report, Invo fertility, inc. (IVF) reported an Operating Profit of -1.64M with an Operating Margin of -93.08% this period, representing a decline of 25.77% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, Invo fertility, inc. (IVF) announced revenue of 1.76M, with a Year-Over-Year growth rate of 22.6%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
As of the end of the reporting period, Invo fertility, inc. (IVF) had total debt of 3.97M, with a debt ratio of 0.21. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
At the end of the period, Invo fertility, inc. (IVF) held Total Cash and Cash Equivalents of 355.89K, accounting for 0.02 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, Invo fertility, inc. (IVF) did not achieve the “three margins increasing” benchmark, with a gross margin of 35.8%%, operating margin of -93.08%%, and net margin of -150.5%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess IVF's profit trajectory and future growth potential.
According to the past four quarterly reports, Invo fertility, inc. (IVF)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -6.2. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
Invo fertility, inc. (IVF)'s Free Cash Flow (FCF) for the period is -1.78M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 178.49% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
The latest valuation data shows Invo fertility, inc. (IVF) has a Price-To-Earnings (PE) ratio of -0.24 and a Price/Earnings-To-Growth (PEG) ratio of 0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.